These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 23513480)
21. Pyomyositis caused by extended-spectrum beta-lactamase-producing Escherichia coli in a patient with acute myeloid leukemia. Chiu SK; Chang FY Int J Infect Dis; 2009 May; 13(3):e85-7. PubMed ID: 18848798 [TBL] [Abstract][Full Text] [Related]
22. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Perea EJ; Pérez-Cano R; Hernández JR; Pascual A Clin Infect Dis; 2006 Jan; 42(1):37-45. PubMed ID: 16323089 [TBL] [Abstract][Full Text] [Related]
23. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors. Ozgunes I; Erben N; Kiremitci A; Kartal ED; Durmaz G; Colak H; Usluer G; Colak E Saudi Med J; 2006 May; 27(5):608-12. PubMed ID: 16680246 [TBL] [Abstract][Full Text] [Related]
24. [Clinical study of the urinary tract infections due to Escherichia coli harboring extended-spectrum beta lactamase]. Hori J; Yamaguchi S; Osanai H; Kinebuchi T; Usami K; Takahashi N; Ishii Y Hinyokika Kiyo; 2007 Nov; 53(11):777-82. PubMed ID: 18051801 [TBL] [Abstract][Full Text] [Related]
25. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Nasa P; Juneja D; Singh O; Dang R; Singh A Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253 [TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974 [TBL] [Abstract][Full Text] [Related]
27. Risk factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli in an urban county hospital. Doernberg SB; Winston LG Am J Infect Control; 2012 Mar; 40(2):123-7. PubMed ID: 21775020 [TBL] [Abstract][Full Text] [Related]
28. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates]. Xiong Z; Zhu D; Zhang Y; Wang F Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910 [TBL] [Abstract][Full Text] [Related]
29. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Kang CI; Chung DR; Ko KS; Peck KR; Song JH; Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875 [TBL] [Abstract][Full Text] [Related]
30. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Kader AA; Angamuthu K Saudi Med J; 2005 Jun; 26(6):956-9. PubMed ID: 15983682 [TBL] [Abstract][Full Text] [Related]
31. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. Rooney PJ; O'Leary MC; Loughrey AC; McCalmont M; Smyth B; Donaghy P; Badri M; Woodford N; Karisik E; Livermore DM J Antimicrob Chemother; 2009 Sep; 64(3):635-41. PubMed ID: 19549667 [TBL] [Abstract][Full Text] [Related]
32. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753 [TBL] [Abstract][Full Text] [Related]
33. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Kanafani ZA; Mehio-Sibai A; Araj GF; Kanaan M; Kanj SS Am J Infect Control; 2005 Aug; 33(6):326-32. PubMed ID: 16061138 [TBL] [Abstract][Full Text] [Related]
34. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368 [TBL] [Abstract][Full Text] [Related]
35. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli. Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056 [TBL] [Abstract][Full Text] [Related]
36. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430 [TBL] [Abstract][Full Text] [Related]